In 1941, the United States entered World War II. Soldiers were dying massively from simple infections because Penicillin was incredibly rare; scientists were literally growing it in tiny glass flasks. The government begged pharmaceutical companies for help. Pfizer, which was just a mid-sized chemical company in Brooklyn, had a highly radical idea. They used the massive fermentation tanks they previously used to make citric acid for Coca-Cola, and attempted to brew Penicillin like beer. The highly risky gamble worked perfectly. They mass-produced the drug, saving millions of Allied soldiers and transforming Pfizer into a global titan.

Founders

Charles Pfizer

Pfizer possesses a historic, immigrant founding story, rooted entirely in the explosive industrial expansion of 19th-century Brooklyn and defined by a brilliant, intensely meticulous German chemist and his ambitious confectioner cousin. The company was founded in 1849 in a modest, red-brick building in Williamsburg, Brooklyn, by Charles Pfizer (a skilled chemist) and his cousin Charles Erhart (a skilled confectioner), who had recently emigrated from Ludwigsburg, Germany. They possessed a specific 'eureka' moment regarding the terrible taste of early medicine. At the time, effective medicine was often foul-tasting, bitter, and difficult to swallow (specifically santonin, a necessary but disgusting drug used to treat parasitic worms). Charles Pfizer understood the complex chemistry required to synthesize santonin. His foundational masterstroke was heavily relying on his cousin Erhart's specific skills as a candymaker. They combined the bitter medicine with a sweet almond-toffee cone, inventing a palatable, commercial success. Their rigorous German commitment to purity and quality control allowed them to expand. During the American Civil War, their big break occurred when they scaled the production of iodine and critical painkillers for the Union Army. However, the world-changing corporate pivot occurred nearly a century later during World War II, when Pfizer pioneered the complex deep-tank fermentation process required to mass-produce life-saving Penicillin, establishing the advanced manufacturing architecture of the modern pharmaceutical industry.

Charles Erhart

Charles Erhart's role in Pfizer's founding is less celebrated than his cousin's, partly because the company carries Charles Pfizer's name and partly because his commercial contributions were less visible than the scientific achievements that drove the company's growth. But the pairing of Erhart's commercial instincts with Pfizer's chemistry expertise represented the classic founding team complementarity that characterized many successful 19th century American manufacturing enterprises. Erhart died in 1891, predeceasing Charles Pfizer by fifteen years, and his interest in the company passed to his family. The company's original name—Charles Pfizer and Company—reflected the naming conventions of the era but understated the genuine partnership that characterized its founding. Historical accounts of early Pfizer consistently credit both founders with the operational and commercial decisions that established the company's reputation for reliability and quality in the specialty chemicals market.

Key Milestones

1849

Pfizer Founded

Charles Pfizer and Charles Erhart founded the company in Brooklyn.

1944

Penicillin Scale-Up

Pfizer helped industrialize penicillin production during World War II.

2000

Warner-Lambert Deal

Pfizer acquired Warner-Lambert, adding Lipitor.

2020

BioNTech COVID Vaccine Partnership

Pfizer and BioNTech brought Comirnaty through emergency authorization.

2023

Seagen Acquisition

Pfizer completed the $43 billion Seagen acquisition.

2025

Chris Boshoff Becomes CSO

Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.

2025

FY2025 Revenue Base

Pfizer reported $62.579 billion of FY2025 revenue.

Major Acquisitions

Warner-Lambert Company

2000

Pfizer pursued Warner-Lambert to acquire the Lipitor (atorvastatin) cholesterol-lowering statin franchise which was already on track to become the best-selling drug in history at the time of the acquisition. The deal was structured as a hostile takeover after Warner-Lambert had announced a competing merger agreement with American Home Products (later Wyeth), and Pfizer outbid with a $111 billion all-stock offer. The acquisition also brought significant consumer healthcare brands including Listerine, Benadryl, and Halls.

Pharmacia Corporation

2003

Pfizer acquired Pharmacia Corporation for approximately $60 billion in 2003 to add the Celebrex (celecoxib) COX-2 inhibitor franchise, the cancer drug Camptosar, ophthalmology products, and a substantial pipeline. The acquisition was also motivated by post-Lipitor diversification concerns and the need to add research capabilities and marketed products to offset anticipated future patent expirations across the combined portfolio.

Wyeth

2009

Pfizer acquired Wyeth for $68 billion during the financial crisis of 2009, using the depressed asset valuations of the period to complete what was then one of the largest pharmaceutical acquisitions in history. The primary strategic targets were the Prevnar pneumococcal vaccine franchise, the Enbrel (etanercept) biologics franchise for rheumatoid arthritis and other inflammatory conditions, the Effexor and Pristiq antidepressants, and Wyeth's substantial consumer healthcare business.

Medivation Inc.

2016

Pfizer acquired Medivation for $14 billion in 2016 to secure Xtandi (enzalutamide), an androgen receptor inhibitor for prostate cancer that was among the most commercially promising oncology drugs of the decade. The acquisition was Pfizer's first major commitment to oncology as a primary strategic growth focus rather than a secondary therapeutic area, signaling a deliberate shift toward cancer treatment as an organizational priority.

Seagen Inc.

2023

Pfizer acquired Seagen for approximately $43 billion in December 2023 to secure leadership in antibody-drug conjugate technology, the fastest-growing drug modality in oncology. Seagen's four commercially approved ADC products—Adcetris, Padcev, Tivdak, and Tukysa—provided immediate revenue contribution while the ADC platform technology provided the foundation for Pfizer's oncology pipeline strategy through 2030. The acquisition represented Pfizer's response to the anticipated loss of exclusivity on Ibrance and the broader need to establish a new oncology platform capable of generating multi-billion-dollar revenues independent of CDK4/6 inhibitor franchise sustainability.

Pfizer Company History FAQ

What are the defining historical milestones for Pfizer Inc.?

Since its establishment in 1849, Pfizer Inc. expanded from an early-stage venture into a recognized leader in Pharmaceuticals & Biotechnology, overcoming key market challenges.

What major strategic pivots shaped Pfizer Inc.'s evolution?

Over its history, Pfizer Inc. executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.

How has Pfizer Inc. adapted to recent industry disruptions?

By continually modernizing operations and embracing workflow automation, Pfizer Inc. maintains resilience through changing technological and economic cycles.